» Articles » PMID: 28042524

Changing the Natural History of Metachronous Gastric Cancer After Eradication

Overview
Date 2017 Jan 3
PMID 28042524
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Metachronous gastric cancer occurs frequently following endoscopic removal of an early gastric cancer. eradication significantly reduces that risk. While, the pathogenesis of this phenomenon remains unclear, it is clear that the natural history of metachronous gastric cancer is altered following eradication. Genetic instability of host cells induced by inflammation, , host or environmental factors can result in the production of malignant cells. eradication reduces and alters the inflammation, and can reverse epigenetic damage and abnormal expression of miRNA's. Fundamentally, eradication stops the progression and may reverse some of the damage to the mucosa resulting in improved acid secretion and improving the gastric microbiome. Because the risk of developing metachronous cancer varies among patients, prospective research is needed to identify reliable biomarkers to predict development of metachronous cancer as well as to define surveillance methods, intervals, and duration. Some candidate examples of prognostic or predictive biomarkers for the prediction of subsequent risk include the presence or absence, titers, and changes in anti-. IgG and or anti-CagA antibodies, serum pepsinogens, gastrin, and miRNAs.

Citing Articles

Guilt by association: intestinal metaplasia does not progress to gastric cancer.

Graham D, Zou W Curr Opin Gastroenterol. 2018; 34(6):458-464.

PMID: 30138135 PMC: 6913177. DOI: 10.1097/MOG.0000000000000472.


Risk of gastric cancer development after eradication of Helicobacter pylori.

Cheung K, Leung W World J Gastrointest Oncol. 2018; 10(5):115-123.

PMID: 29770171 PMC: 5952268. DOI: 10.4251/wjgo.v10.i5.115.


Helicobacter pylori as an oncogenic pathogen, revisited.

Miftahussurur M, Yamaoka Y, Graham D Expert Rev Mol Med. 2017; 19:e4.

PMID: 28322182 PMC: 6905048. DOI: 10.1017/erm.2017.4.


Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits.

Graham D Gastroenterology. 2015; 148(4):719-31.e3.

PMID: 25655557 PMC: 4375058. DOI: 10.1053/j.gastro.2015.01.040.

References
1.
Baggett R, Welsh J . Observations on the effects of glucocorticoid administration in pernicious anemia. Am J Dig Dis. 1970; 15(10):871-81. DOI: 10.1007/BF02236052. View

2.
Lee Y, Chen T, Chiu H, Shun C, Chiang H, Liu T . The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2012; 62(5):676-82. PMC: 3618687. DOI: 10.1136/gutjnl-2012-302240. View

3.
Iishi H, Tatsuta M, Okuda S . Diagnosis of simultaneous multiple gastric cancers by the endoscopic Congo red--methylene blue test. Endoscopy. 1988; 20(2):78-82. DOI: 10.1055/s-2007-1018137. View

4.
Graham D, Shiotani A, El-Zimaity H . Chromoendoscopy points the way to understanding recovery of gastric function after Helicobacter pylori eradication. Gastrointest Endosc. 2006; 64(5):686-90. DOI: 10.1016/j.gie.2006.03.013. View

5.
Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O . CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 2013; 109(2):379-86. PMC: 3721391. DOI: 10.1038/bjc.2013.314. View